FluoroPharma Medical (FPMI) Stock Price, News & Analysis

Company Overview

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FPMI Stock Analysis - Frequently Asked Questions

How were FluoroPharma Medical's earnings last quarter?

FluoroPharma Medical, Inc. (OTCMKTS:FPMI) released its earnings results on Friday, August, 14th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01.

How do I buy shares of FluoroPharma Medical?

Shares of FPMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of FluoroPharma Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FluoroPharma Medical investors own include Adicet Bio (ACET), Marin Software (MRIN), Aurora Cannabis (ACB), AB Corporate Bond ETF (EYEG), Designer Brands (DBI), Capricorn Energy (CNE) and Comcast (CMCSA).

Company Calendar

• Last Earnings: 8/14/2015
• Today: 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:FPMI
• CUSIP: N/A
• CIK: 1402785
• Web: www.fluoropharma.com
• Phone: (973) 744-1565
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 27,580,000
• Free Float: 17,401,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A